This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
NT157 has antineoplastic effects and inhibits IRS1/2 and STAT3/5 in JAK2V617F-positive myeloproliferative neoplasm cells
Signal Transduction and Targeted Therapy Open Access 24 January 2020
-
Signal transducer and activator of transcription STAT5 is recruited to c-Myc super-enhancer
BMC Molecular Biology Open Access 14 April 2016
-
Withacnistin inhibits recruitment of STAT3 and STAT5 to growth factor and cytokine receptors and induces regression of breast tumours
British Journal of Cancer Open Access 01 July 2014
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Levine RL, Gilliland DG . Myeloproliferative disorders. Blood 2008; 112: 2190–2198.
Delhommeau F, Pisani DF, James C, Casadevall N, Constantinescu S, Vainchenker W . Oncogenic mechanisms in myeloproliferative disorders. Cell Mol Life Sci 2006; 63: 2939–2953.
Wernig G, Mercher T, Okabe R, Levine RL, Lee BH, Gilliland DG . Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood 2006; 107: 4274–4281.
Pardanani A, Hood J, Lasho T, Levine RL, Martin MB, Noronha G et al. TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations. Leukemia 2007; 21: 1658–1668.
Goldman JM, Green AR, Holyoake T, Jamieson C, Mesa R, Mughal T et al. Chronic myeloproliferative diseases with and without the Ph chromosome: some unresolved issues. Leukemia 2009; 23: 1708–1715.
Pikman Y, Lee BH, Mercher T, McDowell E, Ebert BL, Gozo M et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 2006; 3: e270.
Grimwade LF, Happerfield L, Tristram C, McIntosh G, Rees M, Bench AJ et al. Phospho-STAT5 and phospho-Akt expression in chronic myeloproliferative neoplasms. Br J Haematol 2009; 147: 495–506.
Nelson EA, Frank DA . Developing pharmacological modulators of STAT signaling. In: Stephanou A (ed). JAK-STAT Pathway in Disease. Landes Bioscience: Austin, 2009, pp 164–172.
Funakoshi-Tago M, Tago K, Abe M, Sonoda Y, Kasahara T . STAT5 activation is critical for the transformation mediated by myeloproliferative disorder-associated JAK2 V617F mutant. J Biol Chem 2010; 285: 5296–5307.
Nelson EA, Walker SR, Weisberg E, Bar-Natan M, Barrett R, Gashin LB et al. The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors. Blood 2011; 117: 3421–3429.
Sikkema AH, Diks SH, den Dunnen WF, ter Elst A, Scherpen FJ, Hoving EW et al. Kinome profiling in pediatric brain tumors as a new approach for target discovery. Cancer Res 2009; 69: 5987–5995.
Rane SG, Reddy EP . Janus kinases: components of multiple signaling pathways. Oncogene 2000; 19: 5662–5679.
Gozgit JM, Bebernitz G, Patil P, Ye M, Parmentier J, Wu J et al. Effects of the JAK2 inhibitor, AZ960, on Pim/BAD/BCL-xL survival signaling in the human JAK2 V617F cell line SET-2. J Biol Chem 2008; 283: 32334–32343.
Yoshimoto G, Miyamoto T, Jabbarzadeh-Tabrizi S, Iino T, Rocnik JL, Kikushige Y et al. FLT3-ITD up-regulates MCL-1 to promote survival of stem cells in acute myeloid leukemia via FLT3-ITD-specific STAT5 activation. Blood 2009; 114: 5034–5043.
Acknowledgements
This work was supported by the Kittredge Foundation (Dana-Farber Cancer Institute), the Brent Leahey Fund (Dana-Farber Cancer Institute), Gabrielle's Angel Foundation (New York, NY), the Claudia Adams Barr Program in Innovative Basic Cancer Research (Dana-Farber Cancer Institute) and Friends of the Dana-Farber Cancer Institute.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies the paper on the Leukemia website
Supplementary information
Rights and permissions
About this article
Cite this article
Bar-Natan, M., Nelson, E., Walker, S. et al. Dual inhibition of Jak2 and STAT5 enhances killing of myeloproliferative neoplasia cells. Leukemia 26, 1407–1410 (2012). https://doi.org/10.1038/leu.2011.338
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2011.338
This article is cited by
-
NT157 has antineoplastic effects and inhibits IRS1/2 and STAT3/5 in JAK2V617F-positive myeloproliferative neoplasm cells
Signal Transduction and Targeted Therapy (2020)
-
Signal transducer and activator of transcription STAT5 is recruited to c-Myc super-enhancer
BMC Molecular Biology (2016)
-
Withacnistin inhibits recruitment of STAT3 and STAT5 to growth factor and cytokine receptors and induces regression of breast tumours
British Journal of Cancer (2014)